BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,088 filers reported holding BAXTER INTL INC in Q3 2020. The put-call ratio across all filers is 1.00 and the average weighting 0.2%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Clearstead Trust, LLC | 3,524 | $283,000 | 0.22% |
| D. E. Shaw & Co., Inc. | 2,730,730 | $219,605,000 | 0.22% |
| ROWLANDMILLER & PARTNERS.ADV | 6,873 | $558,066,000 | 0.22% |
| Sandy Spring Bank | 40,610 | $3,266,000 | 0.22% |
| PARSONS CAPITAL MANAGEMENT INC/RI | 28,398 | $2,284,000 | 0.22% |
| BANQUE PICTET & CIE SA | 183,395 | $14,749,000 | 0.22% |
| Pinnacle Bancorp, Inc. | 3,897 | $313,000 | 0.22% |
| Cottage Street Advisors LLC | 3,725 | $300,000 | 0.22% |
| MARSHALL WACE, LLP | 427,578 | $34,386,000 | 0.22% |
| GLENVIEW STATE BANK TRUST DEPT. | 7,145 | $575,000 | 0.22% |
| BRR OpCo, LLC | 16,123 | $1,297,000 | 0.22% |
| PUBLIC SECTOR PENSION INVESTMENT BOARD | 327,491 | $26,337,000 | 0.21% |
| Diversified Trust Co | 57,349 | $4,612,000 | 0.21% |
| JEPPSON WEALTH MANAGEMENT, LLC | 3,381 | $272,000 | 0.21% |
| Nuveen Asset Management, LLC | 6,874,316 | $552,833,000 | 0.21% |
| Retirement Systems of Alabama | 573,536 | $46,124,000 | 0.21% |
| Field & Main Bank | 3,375 | $271,000 | 0.21% |
| Capital Bank & Trust Co | 192,969 | $15,519,000 | 0.21% |
| Wellington Shields & Co., LLC | 6,150 | $495,000 | 0.21% |
| NEW YORK STATE COMMON RETIREMENT FUND | 2,103,977 | $169,202,000 | 0.21% |
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists BAXTER INTL INC's shareholders in Q3 2020. To view BAXTER INTL INC's shareholder history, click here.